Evidence map›Paper›PMID 25471076›Full record

ArticleInternational journal of public health2015

Estimating diabetes prevalence in Turkey in 2025 with and without possible interventions to reduce obesity and smoking prevalence, using a modelling approach.

Kaan Sözmen, Belgin Unal, Simon Capewell, Julia Critchley, Martin O'Flaherty

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in International journal of public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Kaan SözmenDepartment of Public Health, Faculty of Medicine, Katip Celebi University, Izmir, Turkey, drmelihkaan@hotmail.com.
Belgin Unal
Simon Capewell
Julia Critchley
Martin O'Flaherty
University of Liverpool · GBDokuz Eylül University · TRIzmir Kâtip Çelebi University · TRSt George's, University of London · GB

Funding

Medical Research Council G0900847
6 · The paper itself

Abstract

objectivesThe purpose of this study is to estimate the prevalence and the number of people with type 2 diabetes (T2DM) in 2025 in Turkey and to evaluate the impact of possible policy options on T2DM prevalence.

methodsWe developed a model to predict future prevalence of T2DM using trend data for adults aged 25-74 in Turkey from 1997 to 2025. The model integrates population, obesity and smoking trends to estimate the future T2DM prevalence using a Markov approach.

resultsT2DM prevalence was 7.5% (95% CI: 6.0-9.0%) in 1997 increasing to 16.2% (95% CI: 15.5-21.1%) in 2010. The forecasted prevalence for 2025 was 31.5% (28.6% in men and 35.1% in women). If obesity prevalence declines by 10% and smoking decreases by 20% in 10 years from 2010, a 10% relative reduction in diabetes prevalence (1,655,213 individuals) could be achieved by 2025.

conclusionsDiabetes burden is now a significant public health challenge, and our model predicts that its burden will increase significantly over the next two decades. Tackling obesity and other diabetes risk factors needs urgent action.

Indexed as

AdultAgedDiabetes Mellitus, Type 2FemaleHumansMaleMarkov ChainsMiddle AgedObesityPrevalenceRisk FactorsSmokingSmoking PreventionTurkey

Identifiers

PMID25471076
OpenAlexW2085418225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.